Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines

European Journal of Cancer

Volumn 36, Issue 15, 2000, Pages 1998-2006

  Tokunaga, E ^a   Oda, S ^b   Fukushima, M ^c   Maehara, Y ^a,d   Sugimachi, K ^a,d  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

DNA damage; DNA mismatch repair; p53; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; DNA REPAIR; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033800336     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00200-8     Document Type: Article

References (57)

1. C. Heidelberger N.K. Chaudhuri P. Danenberg Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
2. H.M. Pinedo G.F. Peters Fluorouracil biochemistry and pharmacology J. Clin. Oncol. 6 1988 1653 1664
3. S.M. Swain M.E. Lippman E.F. Egan J.C. Drake S.M. Steinberg C.J. Allegra Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer J. Clin. Oncol. 7 1989 890 899
4. M.A. Poon M.J. O'Connell H.S. Wieand Biochemical modulation of fluorouracil with leucovorin confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer J. Clin. Oncol. 9 1991 1967 1972
5. A.F. Sobrero C. Aschele J.R. Bertino Fluorouracil in colorectal cancer — a tale of two drugs implications for biochemical modulation J. Clin. Oncol. 15 1997 368 381
6. W.B. Parker Y.C. Cheng Metabolism and mechanism of action of 5-fluorouracil Pharmacol. Ther. 48 1990 381 395
7. D.V. Santi C.S. McHenry H. Sommer Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate Biochemistry 13 1974 471 481
8. C. Heidelberger P.V. Danenberg R.G. Moran Fluorinated pyrimidines and their nucleosides Adv. Enzymol. Related Areas of Mol. Biol. 54 1983 58 119
9. H.A. Ingraham B.Y. Tseng M. Goulian Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine Mol. Pharmacol. 21 1982 211 216
10. S. Spiegelman R. Sawyer R. Nayak E. Ritzi R. Stolfi D. Martin Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation Proc. Natl. Acad. Sci. USA 77 1980 4966 4970
11. D.W. Kufe P.P. Major 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity J. Biol. Chem. 256 1981 9802 9805
12. R.I. Glazer L.S. Lloyd Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture Mol. Pharmacol. 21 1982 468 473
13. C.H. Takimoto E.C. Cadman R.D. Armstrong Precursor-dependent differences in the incorporation of fluorouracil in RNA Mol. Pharmacol. 29 1986 637 642
14. C.L. Will B.J. Dolnick 5-Fluorouracil augmentation of dihydrofolate reductase gene transcripts containing intervening sequences in methotrexate-resistant KB cells Mol. Pharmacol. 29 1986 643 648
15. S.L. Doong B.J. Dolnick 5-Fluorouracil substitution alters pre-mRNA splicing in vitro J. Biol. Chem. 263 1988 4467 4473
16. M.M. Gottesman I. Pastan S.V. Ambudkar P-glycoprotein and multidrug resistance Curr. Opin. Genet. Dev. 6 1996 610 617
17. D.M. Bradshaw R.J. Arceci Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance J. Clin. Oncol. 16 1998 3674 3790
18. K.D. Tew A. Monks L. Barone Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program Mol. Pharmacol. 50 1996 149 159
19. P.M. Pil S.J. Lippard Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin Science 256 1992 234 237
20. J.C. Huang D.B. Zamble J.T. Reardon S.J. Lippard A. Sancar HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease Proc. Natl. Acad. Sci. USA 91 1994 10394 10398
21. J.G. Moggs D.E. Szymkowski M. Yamada P. Karran R.D. Wood Differential human nucleotide excision repair of paired and mispaired cisplatin–DNA adducts Nucl. Acids Res. 25 1997 480 491
22. E. Reed Platinum–DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy Cancer Treat. Rev. 24 1998 331 344
23. P. Branch G. Aquilina M. Bignami P. Karran Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage Nature 362 1993 652 654
24. P. Karran M. Bignami DNA damage tolerance, mismatch repair and genome instability Bioessays 16 1994 833 839
25. P. Karran R. Hampson Genomic instability and tolerance to alkylating agents Cancer Surveys 28 1996 69 85
26. D. Fink S. Aebi S.B. Howell The role of DNA mismatch repair in drug resistance Clin. Cancer Res. 4 1998 1 6
27. J.J. Turchi S.M. Patrick K.M. Henkels Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA Biochemistry 36 1997 7586 7593
28. S. Boulton S. Kyle B.W. Durkacz Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage Carcinogenesis 20 1999 199 203
29. A.R. Lehmann B.C. Broughton Poly(ADP-ribosylation) reduces the steady-state level of breaks in DNA following treatment of human cells with alkylatingagents Carcinogenesis 5 1984 117 119
30. P. Branch R. Hampson P. Karran DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines Cancer Res. 55 1995 2304 2309
31. A. Umar M. Koi J.I. Risinger Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6 Cancer Res. 57 1997 3949 3955
32. N.R. Rodrigues A. Rowan M.E. Smith p53 mutations in colorectal cancer Proc. Natl. Acad. Sci. USA 87 1990 7555 7559
33. S.J. Baker A.C. Preisinger J.M. Jessup p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis Cancer Res. 50 1990 7717 7722
34. E. Oki S. Oda Y. Maehara K. Sugimachi Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair Oncogene 18 1999 2143 2147
35. Y. Nakabeppu S. Oda M. Sekiguchi Proliferative activation of quiescent Rat-1A cells by delta FosB Mol. Cell. Biol. 13 1993 4157 4166
36. T. Marunaka Y. Umeno K. Yoshida M. Nagamachi Y. Minami S. Fujii High-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracilplus ftorafur J. Pharm. Sci. 69 1980 1296 1300
37. T. Shirasaka K. Nakano T. Takechi Antitumor activity of 1 M tegafur–0.4 M 5-chloro-2,4-dihydroxypyridine–1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res. 56 1996 2602 2606
38. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
39. H. Okabe H. Tsujimoto M. Fukushima Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil Oncol. Reports 4 1997 685 690
40. C.P. Spears A.H. Shahinian R.G. Moran C. Heidelberger T.H. Corbett In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and-resistant murine colon adenocarcinomas Cancer Res. 42 1982 450 456
41. A.R. Kinsella D. Smith Tumor resistance to antimetabolites Gen. Pharmacol. 30 1998 623 626
42. J. Brugarolas T. Jacks Double indemnity p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in BRCA1 and BRCA2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair Nature Med. 3 1997 721 722
43. P. Nurse Checkpoint pathways come of age Cell 91 1997 865 867
44. J.Y. Wang Cellular responses to DNA damage Curr. Opin. Cell. Biol. 10 1998 240 247
45. M. Fritsche C. Haessler G. Brandner Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents Oncogene 8 1993 307 318
46. W.G. Nelson M.B. Kastan DNA strand breaks the DNA template alterations that trigger p53-dependent DNA damage response pathways Mol. Cell. Biol. 14 1994 1815 1823
47. A.J. Levine J. Momand Tumor suppressor genes the p53 and retinoblastoma sensitivity genes and gene products Biochim. Biophys. Acta 1032 1990 119 136
48. V. Derbyshire P.S. Freemont M.R. Sanderson Genetic and crystallographic studies of the 3′,5′-exonucleolytic site of DNA polymerase I Science 240 1988 199 201
49. D.R. Cross B.J. Miller S.J. James A simplified HPLC method for simultaneously quantifying ribonucleotides and deoxyribonucleotides in cell extracts or frozen tissues Cell Prolif. 26 1993 327 336
50. S.J. James A.G. Basnakian B.J. Miller In vitro folate deficiency induces deoxynucleotide pool imbalance, apoptosis, and mutagenesis in Chinese hamster ovary cells Cancer Res. 54 1994 5075 5080
51. A. Umar J.C. Boyer D.C. Thomas Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability J. Biol. Chem. 269 1994 269
52. P. Modrich Mechanisms and biological effects of mismatch repair Ann. Rev. Genet. 25 1991 229 253
53. M.T. Hawn A. Umar J.M. Carethers Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint Cancer Res. 55 1995 3721 3725
54. H.R. Warner P.A. Rockstroh Incorporation and excision of 5-fluorouracil from deoxyribonucleic acid in Escherichia coli J. Bacteriol. 141 1980 680 686
55. N. de Wind M. Dekker A. Berns M. Radman H. te Riele Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer Cell. 82 1995 321 330
56. S.M. Baker A.W. Plug T.A. Prolla Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over Nature Genet. 13 1996 336 342
57. H. Kawate K. Sakumi T. Tsuzuki Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes Proc. Natl. Acad. Sci. USA 95 1998 5116 5120